🟢 Omada Health is trading 18.73% up today after a Q2 revenue beat and raised 2026 guidance

Omada Health is trading $23.25 (+18.73%) after its August 6, 2026 earnings release showed a Q2 revenue beat and raised 2026 guidance.

• Q2 revenue reached $87.8 million versus $80.0 million consensus; it was the first GAAP-profit quarter, with a record 73% gross margin.
• 2026 revenue guidance rose to $334–$340 million, while adjusted EBITDA guidance increased to $21–$27 million from $14–$20 million.
• President Wei-Li Shao will become CEO on January 1, 2027.